Compare ALH & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALH | XENE |
|---|---|---|
| Founded | 1908 | 1996 |
| Country | United States | Canada |
| Employees | 3973 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | N/A | 2014 |
| Metric | ALH | XENE |
|---|---|---|
| Price | $25.84 | $52.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $30.88 | ★ $68.55 |
| AVG Volume (30 Days) | 507.3K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $7.42 | N/A |
| Revenue Next Year | $5.88 | $2,496.48 |
| P/E Ratio | $35.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.64 | $30.00 |
| 52 Week High | $27.48 | $62.91 |
| Indicator | ALH | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 43.71 |
| Support Level | $23.38 | $39.93 |
| Resistance Level | $26.51 | $59.43 |
| Average True Range (ATR) | 0.94 | 1.71 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 70.32 | 31.53 |
Alliance Laundry Holdings Inc is a designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets. Revenue is generated through the sale of commercial-grade laundry systems and service parts across two geographic segments, North America and International, and into the three end markets of OPL, Vended, and Commercial In-Home.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.